2025-09-30-accounts

Charity registration number: 1092386

NEUROENDOCRINE CANCER UK TRUSTEES' REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2025

WV Chapman Worth Chortered Accountants Chapman Worth Limited

Neuroendocrine Cancer UK Contents

==> picture [503 x 209] intentionally omitted <==

----- Start of picture text -----
|||||||||||| |---|---|---|---|---|---|---|---|---|---|---| |Page| |Trustees’|Report|1—6| |Independent|Examiner's|Report|7| |Statement|of|Financial|Activities|8| |Comparative|Statement|of|Financial|Activities|9| |Statement|of|Financial|Position|10| |Notes|to|the|Financial|Statements|1|1—1|6| |The|following|pages|do|not|form|part|of|the|statutory|accounts:| |Detailed|Statement|of|Financial|Activities|1|7—1|8|

----- End of picture text -----

Neuroendocrine Cancer UK Trustees' Report For The Year Ended 30 September 2025

The trustees present their report and the financial statements for the year ended 30 September 2025.

Objectives and Activities

Aims and Objectives

The constitutional Objectives of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognise, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness, and influencing improvements in outcomes.

The Values we believe in are: (i) equality of care for all neuroendocrine cancer patients in the UK (ii) excellence in support, care, treatment, and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency, and integrity to promote confidence and trust in the charity.

Public Benefit

Neuroendocrine Cancer UK (NCUK) exists to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating neuroendocrine cancer research, increasing national awareness, and influencing improvements in outcomes.

A diagnosis of cancer is one of the greatest challenges anyone can face. Being diagnosed with a rare or uncommon cancer can have additional consequences, not least in terms of awareness, early diagnosis, and access to expertise. Feelings of isolation, fear, uncertainty, and anxiety are not uncommon.

We work hard as an evidence ~~-~~ based advocacy group, collecting real-life data from the community to drive change in both commissioning for neuroendocrine cancer treatments and clinical practice. Our advocacy role is focused on having true impact within a community unaware of the needs of neuroendocrine cancer patients. By sharing our knowledge and patient experience we can collaboratively create positive change. We want to enhance awareness and sel ~~f-~~ confidence within the patient community so they can make informed choices and ask questions. It is vital that the patient voice helps facilitate best practice, that alongside having an input into drug research and development, there is also a safe platform for sharing experiences and peer support. It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, and sadness. For neuroendocrine cancer patients, specifically, the prospect of a cure is often nil, and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis, they can often be treated for the wrong disease, meaning their cancer pathway begins with feelings of extreme frustration. After treatment patients must address the gravity of their diagnosis at home, and often without regular access to the support of experts. Therefore, patients frequently suffer from feelings of abandonment, and struggle to know in whom to confide. Indeed, if their cancer is particularly advanced, they will face the possibility of dying. From our experience, the complexity of neuroendocrine cancer means that friends and family often struggle to comprehend their suffering.

...[CONTINUED]

Page 1

Neuroendocrine Cancer UK Trustees' Report (continued) For The Year Ended 30 September 2025

Public Benefit ~~-~~ continued

People with a less common cancer, like neuroendocrine cancer, are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second ~~-c~~ lass service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experience and to take positive and meaningful steps to address them.

The trustees confirm that they have complied with the requirements of Section 17 of the Charities Act 2011 to have due regard to the Charity Commission’s guidance on public benefit.

Achievements and Performance

Main Achievements

Chief Executive’s Report October 2024 ~~-~~ September 2025

Strengthening our foundations

The period from October 2024 to September 2025 has been one of significant progress and consolidation for Neuroendocrine Cancer UK (NCUK). Throughout the year, we focused on strengthening our foundations while continuing to grow our reach, influence and impact for those affected by neuroendocrine cancer.

We made a strong start on integrating and cleansing our database, an important step that will enable us to use data more effectively as we look ahead. This work supports informed decision ~~-~~ making, strengthens governance, and underpins the delivery of our fiv ~~e-~~ year strategy, launched during the year to guide the next phase of our development.

Expanding patient support and education

We continued to expand and diversify our support and education offer for patients and families. Alongside our patient support groups, counselling services and helpline, we launched a programme of monthly webinars featuring expert speakers. These webinars further empower our community by providing trusted, accessible information to support learning and understanding for patients and their families.

Improving awareness among healthcare professionals

We developed our Spotlight on Neuroendocrine Cancer campaign, aimed at healthcare professionals who are not specialists in neuroendocrine cancer, but who will nonetheless encounter and treat these patients. The campaign focuses on improving awareness of the unique needs of this patient group, providing practical support, and encouraging timely referral into specialist care. This year saw the launch of neuroendocrine cancer patient case studies to support healthcare professionals recognise the disease.

Supporting mental health and wellbeing

As part of the Spotlight on Neuroendocrine Cancer campaign, and in collaboration with Rare Minds, we developed Conversation Openers, an initiative arising from our Open Conversations report on neuroendocrine cancer and mental health. These ‘bitesize’ videos equip healthcare professionals with practical communication strategies to support sensitive conversations around mental health and wellbeing. This work reflects our ongoing commitment to addressing the psychosocial as well as the physical impact of neuroendocrine cancer.

...[CONTINUED]

Page 2

Neuroendocrine Cancer UK Trustees' Report (continued) For The Year Ended 30 September 2025

Main Achievements ~~-~~ continued

Advancing Research

Advancing Research is our campaign dedicated to improving understanding of neuroendocrine cancer through targeted research that makes a real difference for patients and families. This year, we funded a proof ~~-~~ o ~~f-~~ concept research project totalling £50,000, supporting innovative work that could shape future care.

We also entered the second year of our three ~~-~~ year research partnership with the Royal College of Surgeons, contributing £10,000 to fund the first Surgical Specialty Lead (SSL) in neuroendocrine cancer. With only 22 SSLs in the UK, this appointment represents a unique opportunity to drive research, raise awareness, and build expertise within the wider surgical community, ultimately improving care for patients.

In addition, we were delighted to launch a James Lind Alliance (JLA) Priority Setting Partnership (PSP) in neuroendocrine cancer. This important national initiative brings together patients, carers, and healthcare professionals to identify and prioritise the most pressing unanswered questions in diagnosis, treatment, and care. By ensuring research reflects the real experiences and needs of those affected, the PSP is helping shape a more patien ~~t-~~ centred and impactful research agenda.

Recognising Our Community: NCUK Hero Awards

This year, we were proud to launch our Hero Awards, a new initiative designed to recognise the outstanding contributions of individuals within the neuroendocrine cancer community. The awards were created to celebrate the bravery & resilience of those with neuroendocrine cancer, the support and dedication from the medical professionals and the love and support given by their friends & family.

The launch of the Hero Awards generated strong engagement across our community, with nominations and positive feedback reflecting the value placed on recognition and shared experience. The initiative not only highlighted individual achievements but also strengthened community connection, reinforcing the importance of visibility, appreciation and peer support within a condition that is often overlooked.

Community Engagement

This year, our marketing activity was strengthened through the launch of Loop, our new monthly newsletter, designed to engage our audience and highlight our support services, education programmes, campaigns and opportunities to get involved. We significantly increased our social media presence which continues to play a vital role in raising awareness of neuroendocrine cancer and keeping our community informed and connected.

Fundraising and Community Engagement

To strengthen community-led fundraising, we appointed a Community Fundraiser to support, encourage and work alongside individuals and groups raising funds for NCUK. We also supported one of our partners Daily Dip 4 Dave which saw supporters across the UK take part in cold water swimming challenges to raise vital funds for neuroendocrine cancer research.

Collaboration

Collaboration has been a key theme throughout the year, particularly in relation to improving the collation of critical data and enhancing understanding of neuroendocrine cancers. Our work has involved close collaboration with NHS partners, the National Cancer Research Institution (NCRI), the National Cancer Registration and Analysis Service (NCRAS), ENETS Centres of Excellence, expert neuroendocrine multidisciplinary teams, medical and nursing societies, advocacy organisations including Cancer 52 and the International Neuroendocrine Cancer Alliance (INCA), political and policy bodies in the UK and internationally, and engagement with the pharmaceutical industry.

...[CONTINUED]

Page 3

Neuroendocrine Cancer UK Trustees' Report (continued) For The Year Ended 30 September 2025

Main Achievements ~~-~~ continued

None of this work would be possible without the dedication of our staff, trustees, volunteers, partners and supporters. As we look ahead, we do so with confidence, gratitude and a shared commitment to improving outcomes for those affected by neuroendocrine cancer.

Financial Review

Financial Position

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £128,305 (2024 £239,206) for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the Trustees.

At the reporting date the charity held funds of £1,117,726 (2024 £989,421) and the Trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. NCUK receives income through donations and, less regularly, through grants and legacies. Expenditure comprises regular operating costs and project costs. Our reserves policy is to keep reserves to cover 1.5 to 2 years' budgeted regular operating costs

Reference and Administrative Details

Trustees

Mr P Gwilliam ~~-~~ Chairman Dr G Brown Mr D Ames Ms E Brown Mr J Kent Mr T Jackson Dr R Srirajaskanthan

Charity Number

1092386

Principal Address

Second Floor, Holly House 74 Upper Holly Walk Leamington Spa Warwickshire CV32 43L

Independent Examiner

Anna Chapman FCA Chapman Worth Limited

Page 4

==> picture [524 x 726] intentionally omitted <==

|

|

| {

| |

Neuroendocrine Cancer UK Trustees’ Report (continued) a For The Yearie Ended 30 September eR ea 2025

The trustees’ report was approved by the board of trustees and signed on its behalf by:

Mr P Gwilliam

Trustee

Date , 4|4 ¢ —

Page 6

<a

Neuroendocrine Cancer UK

Independent Examiner's Report to the Trustees of Neuroendocrine Cancer UK For The Year Ended 30 September 2025

I report to the trustees on my examination of the accounts of Neuroendocrine Cancer UK (the Trust) for the year ended 30 September 2025.

Responsibilities and Basis of Report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (“the Act”).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

Since the Trust’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or

2. the accounts do not accord with those records; or

3. the accounts do not comply with the applicable requirements concerning the form and contents of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Anna Chapman FCA

Date Chapman Worth Limited Chartered Accountants 2 The Old Estate Yard East Hendred Wantage Oxfordshire OX12 8IY

GW 2026

Page 7

Neuroendocrine Cancer UK Statement of Financial Activities For The Year Ended 30 September 2025

																	2025 2024
																Unrestricted Restricted Total Total
INCOME AND									ENDOWMENTS						Notes	funds funds funds funds £ £ £ £
FROM:
Donations							and legacies								3	594,698 92,525 687,223 709,841
Other				trading				activities							4	2,744 ~~-~~ 2,744 4,107
Investments															5	5,592 ~~-~~ 5,592 6,516
																603,034 92,525 695,559 720,464
EXPENDITURE										ON:
Raising funds															6	(989) ~~-~~ (989) (7,357)
Charitable							activities:								6
Charitable activites																(485,581) (80,684) (566,265) (473,901)
																(486,570) (80,684) (567,254) (481,258)
NET INCOME Transfers between funds															14	116,464 11,841 128,305 239,206 10,797 (10,797) - -
NET			MOVEMENT									IN FUNDS				127,261 1,044 128,305 239,206
RECONCILIATION														OF FUNDS:
Total			funds brought forward													953,050 36,371 989,421 750,215
TOTALFUNDS										CARRIEDFORWARD 14						1,080,311 37,415 1,117,726 989,421

The notes on pages 11 to 16 form part of these financial statements.

Page 8

Neuroendocrine Cancer UK Comparative Statement of Financial Activities For The Year Ended 30 September 2025

																	2024	2024
																Unrestricted Restricted Total
															Notes	funds funds funds £ £ £
INCOME AND								ENDOWMENTS						FROM:
Donations						and legacies									3	604,451 105,390 709,841
Other trading							activities								4	4,107 ~~-~~ 4,107
Investments															5	6,516 ~~-~~ 6,516
																615,074 105,390 720,464
EXPENDITURE									ON:
Raising funds															6	(7,357) ~~-~~ (7,357)
Charitable						activities:									6
Charitable activites																(395,938) (77,963) (473,901)
																(403,295) (77,963) (481,258)
NET			INCOME													211,779 27,427 239,206
NET			MOVEMENT								IN FUNDS					211,779 27,427 239,206
RECONCILIATION													OF FUNDS:
Total			funds brought forward													741,271 8,944 750,215
TOTALFUNDS									CARRIEDFORWARD						14	953,050 36,371 989,421

The notes on pages 11 to 16 form part of these financial statements.

Page 9

|

Neuroendocrine Cancer UK Statement of Financial Position As At 30 September 2025

				2025	2024
		Unrestricted	Restricted	Total	Total
		funds	funds	funds	funds
	Notes	£	£	£	£
CURRENT ASSETS
Debtors	11	4,207	-	4,207	3,084
Cash at bank and in hand		1,091,040	37,415	1,128,455	996,026
		1,095,247	37,415	1,132,662	999,110
Creditors: Amounts Falling Due Within One Year	12	(14,936)	_	(14,936)	(9,689)
NET CURRENT ASSETS (LIABILITIES)		1,080,311	37,415	1,117,726	989,421
TOTAL ASSETS LESS CURRENT LIABILITIES		1,080,311	37,415	1,117,726	989,421
NETASSETS		1,080,311	37,415	1,117,726	989,421
FUNDS OF THE CHARITY
Restricted Funds				37,415	36,371
Unrestricted Funds				1,080,311	953,050
TOTALFUNDS	14			1,117,726	989,421

On behalf of the board

Mr P Gwilliam

Trustee

Date ‘ é

The notes on pages 11 to 16 form part of these financial statements.

Page 10

Neuroendocrine Cancer UK Notes to the Financial Statements For The Year Ended 30 September 2025

1. General Information

Neuroendocrine Cancer UK is an unincorporated charity registered with the Charity Commission, registered charity number 1092386. The principal address is Second Floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4)L.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)", Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities Act 2011.

The charity is a Public Benefit Entity as defined by FRS 102.

2.2.

Incoming Resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

2.3.

Resources Expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

The costs of generating funds consist of fund ~~-r~~ aising event costs and associated merchandise and fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs. Page 11

Neuroendocrine Cancer UK Notes to the Financial Statements (continued) For The Year Ended 30 September 2025

2.4. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other shor ~~t-~~ term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

1. Income from Donations and Legacies

											2025	2025
								Unrestricted Restricted Total
Donations and gifts								funds funds £ £ 491,087 92,525			funds £ 583,612
Legacies								103,611		~~-~~	103,611
								594,698 92,525			687,223
											2024
								Unrestricted Restricted Total
Donations and gifts								funds funds £ £ 456,502 105,390			funds £ 561,892
Legacies								147,949		~~-~~	147,949
								604,451 105,390			709,841
4. Income from Other Trading Activities
								2025			2024
								Unrestricted			Unrestricted
Income from other trading activities								funds £ 2,744			funds £ 4,107
5. Investment		Income						2025			2024
								Unrestricted			Unrestricted
								funds £			funds £
Bankinterestreceivable								5,592			6,516

Page 12

==> picture [524 x 726] intentionally omitted <==

Neuroendocrine Cancer UK Notes to the Financial Statements (continued) For The Year Ended 30 September 2025

==> picture [519 x 515] intentionally omitted <==

----- Start of picture text -----
|||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---| |2024| |Charitable| |activites| |£| |Employee|costs|96,639| |Premises|expenses|12,143| |General|administration|7,542| |Governance|costs|3,887| |120,211| |Support|cost|allocation|for|the|period.| |Office|Expenses|27%|of|the|cost|(2024|13%)| |Legal|&|Professional|53%|of|the|cost|(2024|43%)| |Computer|running|costs|9%|of|the|cost|(2024|9%)| |Rent|&|Rates|100%|of|the|cost|(2024|100%)| |Telecommunications|4%|of|the|cost|(2024|5%)| |Other|costs|92%|of|the|cost|(2024|67%)| |8.|Independent|Examiner's|Remuneration| |2025|2024| |£|£| |Independent|examination|of|the|financial|statements|1,975|3,887| |9.|Staff|Costs| |Staff|costs|were|as|follows:| |2025|2024| |£|£| |Wages|and|salaries|318,291|264,098| |The|number|of|employees|whose|employee|benefits|(excluding|employer|pension|costs)|for|the| |reporting|period|exceeded|£60,000|was:| |2025|2024| |£60,000|to|£69,999|1|1| |10.|Average|Number|of|Employees| |Average|number|of|employees|during|the|year|was:|10|(2024:|11)|

----- End of picture text -----

Page 14

Neuroendocrine Cancer UK Notes to the Financial Statements (continued) For The Year Ended 30 September 2025

11. Debtors

														2025 £	2024 £
Due within one						year
Other debtors														4,207	3,084
12. Creditors: Amounts Falling Due Within One Year
Trade creditors														2025 £ ~~-~~	2024 £ 182
Other creditors														4,765	2,481
Taxation and social security														7,981	4,938
Accruals and deferred income														2,190	2,088
														14,936	9,689

13. Pension Commitments

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund.

During the year the charge to the statement of financial activities in respect of defined contribution schemes was £6,019.

At the statement of financial position date contributions of £1,244 (2024: £939) were due to the fund and are included in creditors.

1. Movement in Funds

								As ati October	As at 30 September
								2024 Income Expenditure Transfers 2025
								£ £ £	£ £
Unrestricted funds
General:
General unrestricted fund								953,050 603,034 (486,570) 10,797 1,080,311
Restricted funds
Restricted fund								36,371 92,525 (80,684) (10,797) 37,415
Total		funds						989,421 695,559 (567,254) ~~-~~ 1,117,726

Page 15

==> picture [524 x 726] intentionally omitted <==

Neuroendocrine Cancer UK Detailed Statement of Financial Activities For The Year Ended 30 September 2025

==> picture [520 x 625] intentionally omitted <==

----- Start of picture text -----
||||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---| |2025|2024| |Total|Total| |funds|funds| |£|£| |INCOME|AND|ENDOWMENTS|FROM:| |Donations|and|legacies| |Donations|and|gifts|583,612|561,892| |Legacies|103,611|147,949| |687,223|709,841| |Other|trading|activities| |Income|from|other|trading|activities|2,744|4,107| |2,744|4,107| |Investments| |Bank|interest|receivable|5,592|6,516| |5,592|6,516| |695,559|720,464| |EXPENDITURE|ON:| |Raising|funds| |Cost|of|raising|funds|(990)|(7,357)| |Employees'|salaries|whose|contracts|are|with|and|are|paid|by|a|related|1|_| |party| |(989)|(7,357)| |Charitable|Activities:| |Charitable|activites| |Strategic|activities|(154,403)|(152,050)| |Professional|costs|(6,414)|-| |Staging|fundraising|events|(6,537)|-| |Subcontractor|costs|-|(7,069)| |Wages|and|salaries|(198,700)|(167,459)| |Travel|and|subsistence|expenses|(8,598)|-| |Computer|software,|IT|consumables|and|maintenance|(1,133)|(1,563)| |Marketing|and|advertising|costs|(2,718)|(9,781)| |Support|and|administration|costs|-|(5,046)| |Data|and|telecommunications|costs|(2,704)|(2,422)| |Printing,|postage|and|stationery|(6,916)|-| |Subscriptions|(508)|-| |Other|direct|costs|-|(661)| |Grants|to|institutions|-|(7,639)| |Grants|to|individuals|(6,439)|-| |Wages|and|salaries|(119,592)|(96,639)| |...|[CONTINUED]|

----- End of picture text -----

Page 17

==> picture [524 x 714] intentionally omitted <==